Imagion Biosystems is pleased to provide its investors with its March 2021 Investor Newsletter. The newsletter details recent new company developments and activities, including: Message
Imagion Biosystems announced on ASX that it has received a total of $54,694.49 for the exercise of options. Please click to review the full announcement
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 16 March 2021. Please click to review the
Imagion Biosystems is pleased to announce it is a proud recipient of an Innovations Connections grant from the Australian Government’s Department of Industry, Science, Energy
Imagion Biosystems announced on ASX that it has received a total of $245,059.82 for the exercise of options. Please click to review the full announcement
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 4 March, 2021. Please click to review the
2020 Highlights: MagSense® HER2 breast cancer Phase I study initiated Collaboration with Siemens Healthineers explores MagSense® nanoparticles using MRI Total of A$12.2 million funds raised
Imagion Biosystems announced on ASX that it has received a total of $299,829.62 for the exercise of options. Please click to review the full announcement
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 18 February, 2021. Please click to review the
The document “Issue of Unlisted Performance Options under Equity Incentive Plan” was lodged with ASX on 9 February 2021. Please click to review the full
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance